Following are the Top 5 companies based on their one-day percentage change within the 'Freight Market 3PL' theme.
iShares MSCI Singapore ETF (EWS)
EWS is trading UP for the last 1 days, and it at trading at $34.19 with volume of 431,636 and a one day change of $0.26 (0.75%). iShares MSCI Singapore ETF has a 52-week low of 26.20 and a 52-week high of $34.25. The business's 50-day moving average price is $31.99 and its 200 day moving average price is $28.86. The firm has a market cap of $1 million, a P/E ratio of 0.00, and a beta of 0.91.
REGN is trading UP for the last 1 days, and it at trading at $798.87 with volume of 237,954 and a one day change of $4.68 (0.59%). Regeneron Pharmaceuticals, Inc. has a 52-week low of 538.23 and a 52-week high of $844.90. The business's 50-day moving average price is $715.96 and its 200 day moving average price is $726.81. The firm has a market cap of $82 million, a P/E ratio of 18.96, and a beta of 0.39.
Top news headlines for REGN
This timeline-focused notice highlights allegations that Regeneron's Phase III Fianlimab-Libtayo disclosures evolved from delayed event accrual to a protocol amendment and then a failed primary endpoint, with REGN investors allegedly absorbing substantial share-price losses This timeline-focused notice highlights allegations that Regeneron's Phase III Fianlimab-Libtayo disclosures evolved from delayed event accrual to a protocol amendment and then a failed primary endpoint, with REGN investors allegedly absorbing substantial share-price losses
LOS ANGELES, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.
Corient Private Wealth LP acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,670 shares of the biopharmaceutical company's stock, valued at approximately $9,148,000. Other large investors also recently
Corient Private Wealth LP cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 23.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,758 shares of the biopharmaceutical company's stock after selling 4,315 shares during the quarter.
This article was generated by KlickAnalytics data insight content engine.
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.
KlickAnalytics AI
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same
analytics engine that powers every screen on this platform — so what comes back is a
number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
NVDA has averaged a 9.2% absolute move on the day after earnings
and closed higher 67% of the time. Two in three reactions land between
−4.2% and +16.3% — the distribution is skewed right,
not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with
“Screen the S&P 500 for oversold quality names.”
“Compare AAPL and MSFT over the last 5 years.”
“What moved the market today, and why?”
“Backtest a 50/200 crossover on TSLA.”
Create a free account to start askingNo credit card required. Confirm your email and the platform is open.